Systematic review with network meta-analysis: Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Vickers, Adrian D ^a   Ainsworth, Claire ^a   Mody, Reema ^b,e   Bergman, Annika ^c   Ling, Caroline S ^a   Medjedovic, Jasmina ^c   Smyth, Michael ^d  

^a RTI HEALTH SOLUTIONS   (United States)

^b TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

^c Takeda Pharmaceuticals International GmbH   (Switzerland)

^d Takeda Global Research and Development Centre Europe   (United Kingdom)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; GOLIMUMAB; INFLIXIMAB; PLACEBO; VEDOLIZUMAB; BIOLOGICAL PRODUCT;

DISEASE SEVERITY; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; ULCERATIVE COLITIS; WOUND HEALING; COLITIS, ULCERATIVE; COMPARATIVE STUDY; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 84992316330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0165435     Document Type: Review

References (42)

1. Crohn's and Colitis UK. Ulcerative colitis Ed 8a-November 2013. Available: https://www.crohnsandcolitis.org.uk/about-inflammatory-bowel-disease/publications/ulcerative-colitis. Accessed 26 May 2016.
2. National Institutes of Health. Ulcerative colitis. June 2010. Available: http://www.nlm.nih.gov/medlineplus/ulcerativecolitis.html. Accessed 4 Sep. 2012.
3. National Institute for Health and Care Excellence. Ulcerative colitis: management in adults, children and young people. June 2013. Available: https://www.nice.org.uk/guidance/cg166/chapter/introduction. Accessed 9 Apr. 2015.
4. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519-525. doi: 10. 1007/s10620-012-2371-5 PMID: 22926499
5. Rubin DT, Dubinsky MC, Panaccione R, et al. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci. 2010;55:1044-1052. doi: 10.1007/s10620-009-0953-7 PMID: 20155319
6. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693-707. doi: 10.1111/j.1365-2036.2010. 04234.x PMID: 20064142
7. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523. doi: 10.1038/ajg.2009.727 PMID: 20068560
8. National Health Service. Ulcerative colitis-treatment. October 2013. Available: http://www.nhs.uk/Conditions/Ulcerative-colitis/Pages/Treatment.aspx. Accessed 16 Apr. 2015.
9. Humira prescribing information. 2011. Available: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125057s0276lbl.pdf. Accessed 17 Jul. 2015.
10. Simponi prescribing information. 2014. Available: http://www.simponi.com/shared/product/simponi/prescribing-information. pdf. Accessed 20 Jul. 2015.
11. Remicade prescribing information. 2015. Available: http://www.remicade.com/shared/product/remicade/prescribing-information. pdf. Accessed 17 Jul. 2015.
12. Entyvio prescribing information. 2014. Available: http://general.takedapharm.com/content/file.aspx? FileTypeCode=ENTYVIOPI&cacheRandomizer=02c52dbe-08bc-45e1-94ef-d1a9b8c5d82b. Accessed 17 Jul. 2015.
13. Mosli MH, MacDonald JK, Bickston SJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:1151-1159. doi: 10.1097/MIB.0000000000000396 PMID: 25844963
14. Taba Taba Vakili S, Taher M, Ebrahimi Daryani N. Update on the management of ulcerative colitis. Acta Med Iran. 2012;50:363-372. PMID: 22837114
15. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704-711. doi: 10.7326/M13-2403 PMID: 24842416
16. Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660-671. doi: 10.1111/apt.12644 PMID: 24506179
17. Mei WQ, Hu HZ, Liu Y, Li ZC, Wang WG. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: a meta-analysis. World J Gastroenterol. 2015;21:6044-6051. doi: 10.3748/wjg.v21.i19.6044 PMID: 26019471
18. de Silva PS, Nguyen DD, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan AN. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther. 2012 Sep; 36(5):459-466. doi: 10.1111/j.1365-2036.2012.05214.x PMID: 22784296
19. Gisbert JP, Marín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015 Apr; 41(7):613-623. doi: 10.1111/apt.13083 PMID: 25652884
20. Wells GGA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence: indirect treatment comparisons in meta-analysis. Ottawa, Ontario, Canada: Canadian Agency for Drugs and Technologies in Health; 2009. Available: www.cadth.ca/media/pdf/H0462-itc-tr-e.pdf. Accessed 27 June 2016.
21. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 1: introduction to evidence synthesis for decision making. 2011 (last updated April 2012). Available: www.nicedsu.org.uk/TSD1%20Introduction. final.08.05.12.pdf. Accessed 27 June 2016.
22. European Medicine Agency. Guideline on the development of new medicinal products for the treatment of ulcerative colitis. 2008. Available: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003266.pdf. Accessed 26 July 2016.
23. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available: http://handbook.cochrane.org/. Accessed 26 May 2016.
24. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535 PMID: 19622551
25. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2014. Available: http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected% 2015April2014.pdf. Accessed 26 May 2016.
26. National Institute for Health and Care Excellence. Specification for manufacturer/sponsor submission of evidence. 2015. Available: https://www.nice.org.uk/Media/Default/About/what-we-do/NICEguidance/NICE-technology-appraisals/specification-for-company-submission-of-evidence-2015-version. docx. Accessed 26 May 2016.
27. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. doi: 10.1056/NEJMoa050516 PMID: 16339095
28. Takeda. Final clinical study report C13006: a phase 3, randomized, placebo-controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe ulcerative colitis (GEMINI-I). Data on file. 4 Sep. 2012.
29. Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel JF, Sandborn W, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Ned. 2013;369(8):699-710.
30. ®) SMC No. (1045/15). May 20015. Available: https://www.scottishmedicines.org.uk/files/advice/vedolizumab-entyvio-FINAL-APRIL-2015-Updated-06.05.15-for-website.pdf. Accessed 9 June 2016.
31. Rutgeerts P. Vedolizumab (VDZ) maintenance therapy for ulcerative colitis (UC): results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. OP280. Oral presentation at the United European Gastroenterology Week 20th Annual Conference (GPSID-13438); 23 October 2012. Amsterdam, The Netherlands.
32. Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Vedolizumab. 15 July 2014. Available: https://www.g-ba.de/informationen/nutzenbewertung/125/. Accessed 9 June 2016.
33. Feagan B, Sands B, Sankoh S, Milch C, Fox I. Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo-controlled, double-blind, multi-centre trial. Poster presented at the ECCO conference; 14-16 February 2013. Vienna, Austria.
34. Parikh A. Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial: O-1b. Inflamm Bowel Dis. 2012;18:S26.
35. ®) for the treatment of adults with moderate to severe active ulcerative colitis. July 2014. Available: https://www.nice.org.uk/guidance/ta342/documents/ulcerative-colitis-moderate-to-severely-activevedolizumabid691-evaluation-report-part-22. Accessed 20 June 2016.
36. R Development Core Team. R version 3.0.1: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013. ISBN 3-900051-07-0. Available: https://www.r-project.org/. Accessed 14 Aug. 2015.
37. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325-337. Available: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.471.604&rep=rep1&type=pdf. Accessed 14 Aug. 2015.
38. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-3124. doi: 10.1002/sim.1875 PMID: 15449338
39. Sturtz S, Ligges U, Gelman A. R2WinBUGS: a package for running WinBUGS from R. J Stat Softw. 2005;12:1-16. Available: http://www.voteview.com/bayes-beach/R2WinBUGS.pdf. Accessed 14 Aug. 2015.
40. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313-2324. doi: 10.1002/sim.1201 PMID: 12210616
41. van der Valk R, Webers CAB, Lumley T, Hendrikse F, Prins MH, Schouten J S AG. A network metaanalysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009;62:1279-1283. doi: 10.1016/j.jclinepi.2008.04. 012 PMID: 19716679
42. Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models. New York, NY: Cambridge University Press; 2007